Oncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Buys 521,739 Shares

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. bought 521,739 shares of the business’s stock in a transaction on Tuesday, February 10th. The stock was bought at an average price of $5.75 per share, for a total transaction of $2,999,999.25. Following the purchase, the insider directly owned 11,931,839 shares of the company’s stock, valued at $68,608,074.25. The trade was a 4.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Oncocyte Price Performance

Shares of Oncocyte stock opened at $5.58 on Friday. The company has a market capitalization of $159.92 million, a P/E ratio of -1.97 and a beta of 1.35. The business has a 50-day moving average price of $6.38. Oncocyte Corp has a one year low of $2.21 and a one year high of $8.51.

Oncocyte (NASDAQ:IMDX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.34) earnings per share (EPS) for the quarter. The firm had revenue of $0.26 million during the quarter. Oncocyte had a negative return on equity of 983.30% and a negative net margin of 1,380.69%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on IMDX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncocyte in a research report on Monday, December 29th. Wall Street Zen raised Oncocyte to a “hold” rating in a research report on Saturday, November 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.